Clinical Trial Update: A Study of Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed Multiple Myeloma Previously Treated With Bortezomib [Phase 2]

View source ↗

Summary

Phase 2 study evaluating bortezomib in combination with pegylated liposomal doxorubicin for relapsed multiple myeloma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Doxil (liposomal doxorubicin)
• Velcade (bortezomib)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Multiple Myeloma | Phase 2 | Status: WITHDRAWN